Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 363 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Tamoxifen Pharmacogenetics and Clinical Effects

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment				Completed				18 to 70				NIGMS				0208-14 UO1-GM61373-05, NCT00228930


2.		Arimidex Observational: Reason for and Effect of Change From Tamoxifen

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				18 and over				Pharmaceutical / Industry				D5392NL0002 ARREST, NCT00246961


3.		Effect of Bazedoxifene, Raloxifene, and Placebo on Breast Density

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Diagnostic, Treatment				Completed				18 to 63				Pharmaceutical / Industry				3068A1-400 NCT00418236


4.		Phase II/III Chemotherapy and Hormone Therapy with ADR/VCR/DBD/PRED Followed by TMX/FXM/BLEO/HMM/MTX-CF for Metastatic Stage III/IV or Recurrent Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 65								WCCC-CO-7711R NCI-D80-048-183


5.		Phase II/III Chemotherapy with CTX/ADR/5-FU/MTX with and without Cell Synchronization with Tamoxifen and Premarin for Metastatic Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 65								NCI-76-C-377A NCI-MB-160A


6.		Phase II/III Chemotherapy with CTX/ADR/MTX/5-FU, with vs without Hormonal Synchronization with TMX/Premarin, for Metastatic Mammary Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								NCI-76-C-377B NCI-MB-160B

Last Modified: 7/5/2006


7.		Phase II/III Randomized Study of TMX/FXM vs TMX/Danazol for Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				NCI-81-C-72 NCI-MB-153, NCI-T83-1460N, T83-1460


8.		Phase II/III Therapy with TMX vs TMX/FXM for Locally Inoperable, Recurrent, or Metastatic Carcinoma of the Breast

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified				NCI				NCCTG-813251 MAYO-813251, NCCTG-81-32-51

Last Modified: 11/1/1988


9.		Phase II/III Multimodality Therapy with Surgery, CTX/ADR/5-FU/TMX/FLU, plus Radiotherapy for Stage III Breast Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 to 69								WCCC-CO-8111 NCI-D81-048-515


10.		Phase II/III Endocrine Therapy with AG/TMX/HC vs TMX Alone for Metastatic or Recurrent Breast Carcinoma, with AG/HC for Patients with Prior TMX

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				postmenopausal								MAYO-803201

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute